Filing exhibits
- 8-K Current report
- 10.1 Offer Letter Dated, February 6, 2024, Between Cadrenal Therapeutics, Inc. and Jeffrey Cole
- 10.2 Employment Agreement, Effective As of February 8, 2024, Between Cadrenal Therapeutics, Inc. and Jeffrey Cole
- 99.1 Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
- Download Excel data file
- View Excel data file
Table of Contents